Summary Lonidamine or 1-[(2, 4-dichlorophenyl) methyl]-lH-indazole-3-carboxylic acid, studied in a battery of in vitro and in vivo tests currently used for the screening of anti-tumour agents affecting cell division, has been shown to have a narrow spectrum of anti-tumour activity. The significance of this finding is discussed in the light of previous investigations suggesting that lonidamine affects mitochondrial function and not cell replication. Hyperthermia has been shown to sensitize tumour cells to lonidamine. This observation indicates that in combination with hyperthermia lonidamine has some potential for the treatment of cancer; moreover, it suggests that hyperthermia might reproduce a metabolic condition occurring in some stages of the disease. The blood levels corresponding to the anti-tumour action of lonidamine in animals are in the range of those detected in patients treated with the drug.
Lonidamine or 1-[(2,4-dichlorophenyl)methyl]-1H-indazole-3-carboxylic acid is the most potent derivative of a series of indazole carboxylic acids which originally aroused interest on account of their anti-spermatogenic activity observed at very low doses in comparison with those producing general toxicity (Corsi et al., 1976) . It has also been reported that the potency of anti-spermatogenic activity varies ten-fold between the different members of this series without any parallel changes in their general toxicity . Subsequent studies have shown that lonidamine also possesses embryotoxic (Scorza Barcellona et al., 1982) and anti-tumour effects (Caputo, 1981; Silvestrini, 1981) . Unlike general toxicity, these effects show a quantitative correlation with antispermatogenic activity along the different indazole carboxylic derivatives, suggesting the involvement of a common mechanism (Silvestrini, 1981) .
There is no indication that lonidamine affects cell division (Heywood et al., 1981) . Instead, ultrastructural and biochemical studies have suggested that the mitochondria might represent the primary target for the anti-spermatogenic action (Floridi et al., 1980; 1981; Silvestrini, 1981) . During spermatogenesis, the mitochondria of germ cells pass, according to the definition of Hackenbrock (1966; 1968) from the "orthodox" to the "condensed" form (Fawcett, 1970; Machado et al., 1972; De Martino et al., 1979) . Condensed mitochondria have also been described in tumour cells in some particular experimental conditions 0007-0920/83/020221-11 $02.00 c (Hackenbrock et al., 1971) . Hence the hypothesis that the condensed mitochondria, which represent an adaptive phenomenon of cell metabolism to high energy requirements, might represent a specific target for the action of lonidamine (Silvestrini, 1981) . It has also been observed that in germ cells the inhibition of respiration produced by lonidamine is accompanied by a compensatory increase of aerobic glycolysis, whilst in tumour cells both respiration and aerobic glycolysis are inhibited, possibly on account of the importance of mitochondrially-bound hexokinase in these cells (Floridi et al., 1981a) . This paper reports the effects of lonidamine, alone or in combination with hyperthermia, on some tumour-host systems currently used in the screening of anti-tumour agents. Hyperthermia has been used both for practical reasons and on the assumption that it might induce the appearance of condensed mitochondria which according to earlier reports could represent the target for the action of lonidamine. Since literature on this subject is lacking, the eventual appearance of condensed mitochondria under the influence of hyperthermia has been checked with the electron microscope.
Materials and methods
In vitro tests The in vitro tests were conducted as described by Geran et al. (1972) ; cytotoxicity was assayed by cell enumeration. The most significant points of these tests were as follows:
Human epidermoid carcinoma cells of the nasopharynx (KB cells) were maintained in monolayer culture in Eagle's minimum essential (j The Macmillan Press Ltd., 1983 222 B. SILVESTRINI, G.M. HAHN, V. CIOLI & C. DE MARTINO medium (MEM)+ 10% calf serum (CS). Control tubes were required to exhibit growth of at least 6 x that of baseline tubes. The assay was run for 4 days. Lonidamine (ACRAF Rome) was dissolved (400 ug ml -') in dimethylsulphoxide (DMSO) and diluted with the medium to obtain the final test concentrations. 6-mercaptopurine (Sigma, London), used as positive control, exhibited an active dose (ED50) of 0.05-0.5 jugml-.
P-388 lymphocytic leukaemia cells were propagated as a suspension culture in Fischer's medium + 10% horse serum. Untreated control tubes were required to exhibit growth 9 x that of baseline tubes. The assay was run for 2 days. Lonidamine was dissolved as described above. Methyl-lomustine (MeCCNU) (ACRAF-Rome), used as positive control, showed an ED50 of 1.77-7 gml m'.
HeLa human carcinoma cells were cultured using Eagle's MEM + 10% CS +0.1% neomycin. The assay was run for 2 days. Since in this test the effective concentrations of lonidamine were in the range of its water solubility, DMSO was avoided. A 0.02% solution of lonidamine was prepared by adding 18mg of product to 2 ml of 0.1 M NaOH. The mixture was heated to 45°C and 5 ml of distilled water were added under stirring until complete dissolution occurred. Finally, 38 ml of 0.1 M NaOH and 0.69 g of NaH2PO4H20 were added and the volume was adjusted to 90 ml with distilled water.
In this test, AF 1312/TS (1-p-chlorobenzyl-lH indazol-3-carboxylic acid) (ACRAF Rome) was used as a reference compound. A 0.2% aqueous solution of AF 1312/TS was prepared by dissolving 190mg of the compound in 45 ml of 0.1 M NaOH. Fifty ml of NaH2PO4 0.1 M was then added. For both compounds the final pH was 7.3. In vitro tests with heating Cells and Culture Conditions Cells from a Chinese hamster cell line (HA-1) of ovarian origin were maintained in Eagle's MEM + 15% foetal calf serum (FCS) and antibiotics; the cultures were maintained in a humidified incubator in 5% CO2 in air and routinely checked for mycoplasma. Exponentially growing cells were used for all experiments; plating efficiencies were 70-90%. In all experiments, media were exchanged just prior to the exposure of cells to either heat or drug. After such exposure, the monolayers of cells were rinsed at least twice with phosphate-buffered saline (PBS). Cells were then trypsinized and plated at appropriate dilutions for colony formation. Cell survival was assayed by the cloning technique of Puck & Marcus (1956) .
Heating Monolayers of cells on plastic petri dishes were exposed to elevated temperatures in purpose-built hot water baths in incubators. The pH of the media overlaying the cells was maintained by a regulated gas flow of a mixture of 5% CO2 in air to values 7.2-7.4. The temperature was maintained to 43°C + 0.1°C; the time required to reach equilibrium was about 3 min and was included in the quoted heating times. The duration of heating was varied in steps of 1 h. Lonidamine and AF 1312/TS were dissolved in DMSO; the concentrations are given in Table 2 . Cells were exposed to drugs 1 h before and during heating. In all experiments, media were renewed prior to the exposure of cells to either heat or drug.
In vivo tests
Unless otherwise indicated, the tests were performed according to the procedures outlined in the NCI Protocols for Screening of Anti-Cancer Compounds (Geran et al., 1972 The melanotic melanoma B-16 was propagated as a tumour homogenate (1 g of tumour with lOml of BSS) in DBF1 mice. The homogenate (0.5 ml) was injected i.p.
The ependymoblastoma is a mutant subline of an original methylcholanthrene-induced tumour. A 1 mm3 tumour fragment was implanted intracranially in B6C3F1 mice by trocar. Treatment was for 5 days.
Lewis lung carcinoma was propagated by s.c. implantation of an 8 mm3 tumour fragment in the axillary region of BDF1 mice. Treatment was given daily for 9 days p.o., i.p. or in the form of medicated diet. In the latter case, the animals were housed individually and food consumption was determined daily.
The Ehrlich ascites was studied in CF1 mice. Tumour cells were adjusted to 6 x 106 and implanted i.p. Treatment was administered as described for the Lewis Lung tumour.
Sarcoma 180 (S180) was propagated in the ascitic form in CF1 mice. Tumour cells were adjusted to 6 x 106 and implanted i.p. Experiments were also performed with the solid form of S180. A fragment of 40 mg was implanted s.c. into the dorsum. Unless otherwise indicated, S180 will refer to the ascitic form of this tumour.
Among the S180 and Ehrlich ascites recipients, there was a small percentage of tumour-free animals. Since they were equally distributed in the control and treated animals it was decided aebitrarily not to include these animals in the analyses. The animals were observed for 3 months or until death.
Serum and ascites concentrations of lonidamine Concentrations of lonidamine in serum and ascites were determined according to the method of Catanese et al. (1978) . The compound was extracted with n-heptane. Fluorimetric assay was performed using excitation and emission wavelengths of 305 and 345 nm respectively (uncorrected values). The sensitivity of the method was 1 jigml-' serum or ascites. The identity of diclondazolic acid was checked by thin layer chromatography, using a method applied to AF 1312/TS (Burberi et al., 1975) .
In vivo tests with heating Experiments were performed on S180-or Ehrlich ascites-bearing mice, implanted as described above. Heating was commenced 3 days following implantation of tumours essentially as described by Cioli & Silvestrini (1971 Table I summarizes the effects of lonidamine, AF 1312/TS and reference compounds on KB, P-388 and HeLa cells.
Results

In vitro tests
Lonidamine produced no decrease in KB tumour cell growth in the concentration range from 1-10gml-1 but was effective at 100ugml-'; 6-mercaptopurine, used as a positive control, was effective from 1 jig ml-1.
The effects of lonidamine in the P-388 test were similar to those observed with the KB cells. MeCCNU, used as a positive control was effective at 10 jg ml -. In the HeLa test, lonidamine decreased tumour cell growth at 10 jug ml-. AF 1312/TS was active at concentrations 2.5 x greater than lonidamine, i.e. at 25 jg ml-'.
In vitro tests with heating Table II shows the effects of lonidamine and AF 1312/TS on survival of Chinese hamster cells (HA-1) heated at 430C.
These results clearly show that in the presence of even small amounts of lonidamine, there was an Nine days treatment at 50mg kg-' p.o. daily produced a 25% increase in life span which was not significant; no effect was observed with 100mgkg-1 p.o. daily. Fifteen days treatment at 100mgkg-' p.o. daily, decreased the life span. Lonidamine was inactive when given in the medicated diet. Table 5 summarizes the results of experiments performed with S180.
A 22% increase of life span was observed with 25 mgkg-1 p.o. of lonidamine. This value was lower than the one considered indicative of anti-tumour action (Geran et al., 1972) and was not statistically significant. This was supported by the lack of effect at 50 and l00mgkg-I p.o. These doses are much lower than those producing general toxicity (see Table III ).
Administration of lonidamine in the diet resulted in a dose-related increase in life span. AF 1312/TS was as active as lonidamine at 10 x the dose, i.e. 1250mg kg-' compared with 125mg kg-1 lonidamine in the diet. Using the S180 in the solid form the efficacy of lonidamine was confirmed.
Serum and ascites concentrations of lonidamine Lonidamine was measured in the serum of normal and S180-bearing animals following exposures of different duration via the diet. In tumour-bearers, treatment was commenced concomitantly with tumour implantation. The daily doses of 125 and 250mg kg-1 correspond to those which in the previous experiments produced a significant increase in life span. The results are summarized in Table VI . In tumour bearers, these doses produced serum concentrations in the range of 12-22 and 18-28 ug ml-1 respectively; similar concentrations were found in the ascitic fluid. During the first week of treatment the serum concentrations were higher in normal animals than in tumour-bearers; no appreciable difference was observed the following week. Body fluid levels of lonidamine were also estimated in mice with Ehrlich ascites which, in the previously described experiments, proved to be resistant to lonidamine. The drug was given in the diet at a daily dose of 250mgkg-' (0.17%). The animals were killed and examined after 7 days of treatment. The concentrations were 17.9+1.61 and 22.3+2.14pgml-' in the serum and ascitic fluid respectively.
In vivo tests with heating Table VII summarizes the effects of lonidamine and heating, both alone and together, on S180 and Ehrlich ascites in mice. Treatments were performed daily on days 3-6 following tumour implantation.
Lonidamine alone at the daily dose of 50mgkg-p.o., had no effect on S180. Combination with heat resulted in a 29% increase in life span.
Lonidamine at the daily dose of 25 or 50mg kg-1 p.o. did not significantly increase the life span of Ultrastructural observations Two main types of Ehrlich ascites tumour cells were visible in the untreated controls. The first type was more numerous and characterized by mitochondria with lamellar cristae (Figure 1 ), regularly arranged (orthodox form); the second type revealed mitochondria with dense matrix and expanded intercristal space (Figure 2 ) or condensed-like form . 
Discussion
These experiments provide data on three issues which will be discussed separately: (i) the narrow spectrum of activity of lonidamine in the battery of tests currently used for the screening of anti-tumour agents; (ii) its anti-tumour activity in combination with hyperthermia; (iii) the blood levels corresponding to anti-tumour activity in a specific bioassay relative to those found in man (Besner et al., 1981 unpublished) .
(i) The tumour systems currently used for the screening of anti-tumour agents differ sharply from naturally-occurring neoplasms; not only are they based upon transplantable tumours, but the tumour-host relationship (which seemingly influences the course of natural diseases) is altered. Responsiveness to currently available anti-tumour agents has been the principal, if not the only, criterion for the choice of these systems (Gellhorn & Hirschberg, 1955; Goldin et al., 1966; Wood, 1977) . There are however, some evident limitations attached to this policy of screening anti-tumour agents. Most of the presently available agents are similar in their basic mechanism of action, viz., they are anti-mitotics. Consequently, screening focuses on a specialized type of anti-tumour activity, and there is no evidence that it will eventually identify agents which act by different mechanisms. Such might be the case with lonidamine. All the available data indicate that this drug primarily affects the energy metabolism (and not the replicative process) of the cancer cell and this should be taken into account when interpreting the results of this study. Thus, they do not necessarily indicate that lonidamine is a narrow spectrum anti-tumour agent, but rather that current experimental tumour models are unsuitable for the study of drugs acting on the energy metabolism of the cell.
(ii) The study of hyperthermia relates to both the problem of the mechanism of action of lonidamine and its potential therapeutic interest in combination with hyperthermia. As stated in the Introduction, previous studies indicate that the condensed mitochondrion is the target for the activity of lonidamine (Floridi et al., 1980; 1981; Silvestrini, 1981) . Hyperthermia was studied on the basis of the speculation that it could produce an imbalance between energy requirements and the oxygen supply of the tumour cells, thus leading to the formation of condensed mitochondria. This has been corroborated here by ultrastructural observations showing the appearance of condensed mitochondria under the influence of hyperthermia. The finding that a degree of hyperthermia, inactive alone, has significant anti-tumour activity when combined with lonidamine is in agreement with the working hypothesis that the state of the energy metabolism of the cell is the critical factor for the activity of lonidamine, but is not conclusive. The question whether hyperthermia reproduces a metabolic state in experimental tumours which also occurs in some stages of naturally-occurring tumours is of practical importance, but cannot be answered by data presently available. Apart from these theoretical considerations, our data suggest a potential use of the lonidamine-hyperthermia combination in the treatment of cancer. A recent study (Kim et al., 1982) has confirmed that lonidamine potentiates the anti-tumour activity of hyperthermia both in vivo and in vitro, showing that in vitro pH represents a critical factor for this phenomenon.
(iii) The doses of lonidamine active on S180 have been shown to correspond to blood concentrations in the range of 12-28 yg ml-1; since these blood levels are in the range of those detected in patients treated with lonidamine (Besner et al., 1981 unpublished) , these results further stress the potential of lonidamine for the treatment of cancer.
